Pinteon Therapeutics Overview

  • Founded
  • 2014
  • Status
  • Private
  • Employees
  • 7
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $17M
Latest Deal Amount
  • Investors
  • 1

Pinteon Therapeutics General Information


Developer of a novel antibody intended to maintain brain health of the patients. The company's antibody interrupts the spread of toxic tau and protects and preserves brain function in patients suffering from neurodegenerative disease, enabling doctors to normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 1188 Centre Street
  • Newton, MA 02459
  • United States
+1 (917) 000-0000

Pinteon Therapeutics Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pinteon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 31-Oct-2019 $17M 0000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-Aug-2017 0000 0000 000.00 Completed Startup
To view Pinteon Therapeutics’s complete valuation and funding history, request access »

Pinteon Therapeutics Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Pinteon Therapeutics’s complete cap table history, request access »

Pinteon Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Martin Jefson Ph.D Chief Executive Officer
Michael Ahlijanian Ph.D Chief Scientific Officer
Larry Altstiel Ph.D Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Pinteon Therapeutics Board Members (3)

Name Representing Role Since
Jason Dinges Ph.D Morningside Group Board Member 000 0000
Jeffrey Ives Ph.D Self Chairman 000 0000
Westley Nolin Ph.D Self Board Member 000 0000
To view Pinteon Therapeutics’s complete board members history, request access »

Pinteon Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pinteon Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Morningside Group Venture Capital Minority 000 0000 000000 0
To view Pinteon Therapeutics’s complete investors history, request access »